Pneumococcal vaccine development is driven by the achievement of high activity in a single gatekeeper assay: the bacterial opsonophagocytic killing (OPK) assay. New evidence challenges the dogma that anti-capsular antibodies have only a single function that predicts success. The emerging concept of multi-modal protection presents an array of questions that are fundamental to adopting a new vaccine design process. If antibodies have hidden non-opsonic functions that are protective, should these be optimized for better vaccines? What would protein antigens add to protective activity? Are cellular immune functions additive to antibodies for success? Do different organs benefit from different modes of protection? Can vaccine activities beyond OPK protect the immunocompromised host? This commentary raises these issues at a time when capsule-only OPK assay-based vaccines are increasingly seen as a limiting strategy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963391 | PMC |
| http://dx.doi.org/10.3390/pathogens8040203 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The eye movement and gait variability analysis in Chinese patients with Huntington's disease.
J Mov Disord
December 2024
Department of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine and Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou, China.
Background: Huntington's disease disease (HD) is characterized by motor, cognitive, and neuropsychiatric symptoms. Oculomotor impairments and gait variability have been independently considered as potential markers in HD. But there lacks an integration analysis of eye movement and gait.
View Article and Find Full Text PDFOculomotor Findings in Videonystagmography across the Lifespan.
J Am Acad Audiol
February 2023
Department of Audiology and Speech Pathology, University of Tennessee Health Science Center, Knoxville, Tennessee.
Background: When performing oculomotor testing during standard videonystagmography (VNG), the vestibular system is not actively stimulated. Therefore, responses are generated from the cerebellum, brainstem, and oculomotor tract. Many patients seen for vestibular testing fall outside of the standard age norms, making it difficult to determine whether an abnormal finding is due to age or oculomotor dysfunction.
View Article and Find Full Text PDFImmunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
Vaccine
September 2024
Department of Medicine, University of Tennessee Health Science Center, 956 Court Ave., Memphis, TN 38163, USA. Electronic address:
Background: Group A Streptococcus (Strep A) causes both uncomplicated and severe invasive infections, as well as the post-infection complications acute rheumatic fever and rheumatic heart disease. Despite the high global burden of disease resulting from Strep A infections, there is not a licensed vaccine. A 30-valent M protein-based vaccine has previously been shown to be immunogenic in animal models and in a Phase I clinical trial (NCT02564237).
View Article and Find Full Text PDFMeconium Proteins Involved in Iron Metabolism.
Int J Mol Sci
June 2024
Department of Biochemistry and Pharmacogenomics, Medical University of Warsaw, 02-097 Warsaw, Poland.
The lack of specific biological materials and biomarkers limits our knowledge of the mechanisms underlying intrauterine regulation of iron supply to the fetus. Determining the meconium content of proteins commonly used in the laboratory to assess the transport, storage, and distribution of iron in the body may elucidate their roles in fetal development. Ferritin, transferrin, haptoglobin, ceruloplasmin, lactoferrin, myeloperoxidase (MPO), neutrophil gelatinase-associated lipocalin (NGAL), and calprotectin were determined by ELISA in meconium samples obtained from 122 neonates.
View Article and Find Full Text PDFA Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of in Patients with Bronchiectasis.
Am J Respir Crit Care Med
July 2024
Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
Article Synopsis
- Patients with bronchiectasis experience worse health outcomes due to infections, often linked to weakened neutrophil antimicrobial responses that allow bacteria to persist.
- The study investigated the effectiveness of gremubamab, a bispecific monoclonal antibody, in boosting the ability of neutrophils to kill bacteria associated with bronchiectasis.
- Results showed that gremubamab significantly improved neutrophil functions, including opsonophagocytic killing and phagocytosis, without interfering with the body's natural antibodies, thus reducing the harmful effects of the bacterial infection.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!